INNATE PHARMA SA (IPHA): Price and Financial Metrics
IPHA Price/Volume Stats
Current price | $2.57 | 52-week high | $3.57 |
Prev. close | $2.49 | 52-week low | $1.81 |
Day low | $2.48 | Volume | 1,700 |
Day high | $2.57 | Avg. volume | 10,182 |
50-day MA | $2.51 | Dividend yield | N/A |
200-day MA | $2.63 | Market Cap | 207.81M |
IPHA Stock Price Chart Interactive Chart >
INNATE PHARMA SA (IPHA) Company Bio
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.
Latest IPHA News From Around the Web
Below are the latest news stories about INNATE PHARMA SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to SanofiMARSEILLE, France, December 19, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible |
Innate Pharma Announces Leadership ChangeMARSEILLE, France, December 18, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company. |
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023MARSEILLE, France, December 11, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that the updated efficacy and safety results from an open-label, first-in-human, Phase 1/2 dose-escalation study of SAR443579 / IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE) from a joint research collaboration between Innate Pharma and Sanofi were shared in a poster presentation at the American So |
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023MARSEILLE, France, December 10, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California. |
Innate Pharma to Host Virtual KOL Event on LacutamabMARSEILLE, France, November 27, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET). |
IPHA Price Returns
1-mo | -1.15% |
3-mo | 4.05% |
6-mo | 8.44% |
1-year | -15.74% |
3-year | N/A |
5-year | N/A |
YTD | -8.21% |
2023 | -24.93% |
2022 | -18.20% |
2021 | 11.49% |
2020 | -36.49% |
2019 | N/A |
Loading social stream, please wait...